List of Diprivan drug patents

Diprivan is owned by Fresenius Kabi Usa.

Diprivan contains Propofol.

Diprivan has a total of 2 drug patents out of which 0 drug patents have expired.

Diprivan was authorised for market use on 02 October, 1989.

Diprivan is available in injectable;injection dosage forms.

The generics of Diprivan are possible to be released after 01 June, 2025.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8476010 FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Dec, 2024

(1 year, 10 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476010

(Pediatric)

FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Jun, 2025

(2 years from now)

Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DIPRIVAN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic